# FAKTION (NCT01992952)

> Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01992952
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Velindre NHS Trust
- Conditions: Estrogen Receptor Positive Breast Cancer
- Interventions: AZD5363; Placebo; Fulvestrant
- Enrollment: 149
- Primary outcome: Phase 1b primary outcome measure: Maximum Tolerated Dose of AZD5363 in combination with fulvestrant
- Primary outcome: Phase 2 primary outcome: Progression free survival (PFS)

## Commentary we found

- Podcasts: 5
- YouTube: 3
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=faktion-nct01992952

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01992952", "email": "<work email>"}; the inbox owner confirms by the emailed link.